Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Liz Robertson"'
Publikováno v:
Development (Cambridge, England)
Development (Cambridge, England), 2021, 148 (18), ⟨10.1242/dev.200137⟩
Development (Cambridge, England), 2021, 148 (18), ⟨10.1242/dev.200137⟩
International audience
Autor:
Neeraj Agarwal, Judit Kocsis, Charles P. Theuer, Mohamed Darif, Jing Lyu, Sumanta K. Pal, Bonne J. Adams, Mollie deShazo, Kouros Owzar, Thai H. Ho, Toni K. Choueiri, Liz Robertson, Yousef Zakharia, Andrew B. Nixon, Meghara K. Walsh, Russell K. Pachynski, Lajos Géczi, Yingmiao Liu, Alexandr Poprach, Primo N. Lara, Mark D. Starr
Publikováno v:
The oncologist, vol 26, iss 7
Oncologist
Oncologist
Lessons Learned Background Endoglin is an angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of resistance to vascular endothelial growth factor receptor (VEGFR) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cb3cefb1fe953ed4cc21558dbfb65ff
https://escholarship.org/uc/item/6xc9d29b
https://escholarship.org/uc/item/6xc9d29b
Autor:
Robin L. Jones, Vinod Ravi, Andrew S. Brohl, Sant Chawla, Kristen N. Ganjoo, Antoine Italiano, Steven Attia, Melissa A. Burgess, Katherine Thornton, Lee D. Cranmer, Maggie Chon U. Cheang, Lingyun Liu, Liz Robertson, Bonne Adams, Charles Theuer, Robert G. Maki
Publikováno v:
JAMA Oncology. 8:740
Angiosarcoma is a rare sarcoma subtype with a poor outcome. Carotuximab plus pazopanib produced a median progression-free survival (PFS) of 7.8 months in pazopanib-naive patients with chemotherapy-refractory angiosarcoma in a phase 1/2 trial.To deter
Publikováno v:
Contemporary Crises. 12:91-106